Syncom Formulations India Ltd vs Venus Remedies Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Syncom Formulations (India) Ltd is ₹ 14.06 as of 05 May 15:30 . The P/E Ratio of Syncom Formulations (India) Ltd changed from 46.2 on March 2022 to 0 on March 2021 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Venus Remedies Ltd changed from 8.8 on March 2022 to 5.5 on March 2021 . This represents a CAGR of -8.97% over 5 years The Market Cap of Syncom Formulations (India) Ltd changed from ₹ 916.79 crore on March 2022 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 5 yearsThe Market Cap of Venus Remedies Ltd changed from ₹ 359.37 crore on March 2022 to ₹ 338.91 crore on March 2021 . This represents a CAGR of -1.17% over 5 years The revenue of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 120.64 crore as compare to the Sep '25 revenue of ₹ 126.97 crore. This represent the decline of -4.99% The revenue of Venus Remedies Ltd for the Dec '25 is ₹ 182.78 crore as compare to the Sep '25 revenue of ₹ 194.46 crore. This represent the decline of -6.01% The ebitda of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 26.71 crore as compare to the Sep '25 ebitda of ₹ 23.65 crore. This represent the growth of 12.94% The ebitda of Venus Remedies Ltd for the Dec '25 is ₹ 40.04 crore as compare to the Sep '25 ebitda of ₹ 32.67 crore. This represent the growth of 22.56% The net profit of Syncom Formulations (India) Ltd changed from ₹ 7.63 crore to ₹ 18.91 crore over 7 quarters. This represents a CAGR of 67.97% The net profit of Venus Remedies Ltd changed from ₹ 1.22 crore to ₹ 25.58 crore over 7 quarters. This represents a CAGR of 469.07% The Dividend Payout of Syncom Formulations (India) Ltd changed from 13.07 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 yearsThe Dividend Payout of Venus Remedies Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Syncom Formulations (India) Ltd

Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992.
The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency.
Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards.
Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations.

About Venus Remedies Ltd

Incorporated in 1989 Venus Remedies Limited, formerly known as Venus Glucose Pvt Ltd, was converted into Public Limited Company in 1994 and then changed into Venus Remedies Limited.
The Company was promoted and managed by Chaudhary & Family.
The Company is one of the handful player in pharmaceutical sector to launch injectables globally.
It has manufacturing facilities in Panchkula and Baddi , and research and development centre under the name of Venus Medicine Research Centre (in India). At present, Venus focuses on specialized therapeutic areas including anti-infectives (antibiotics), oncology, neurology, pain management, and skin and wound care.
In priority, the Company was mainly engaged in I/V Fluids & Injectables, Ceftazidime, Amlodipine, Gliclazide, Lisinopril, etc. The production was started in 1991 with Intravenous/Intramuscular injectible forms at Panchkula district at Haryana.

FAQs for the comparison of Syncom Formulations (India) Ltd and Venus Remedies Ltd

Which company has a larger market capitalization, Syncom Formulations (India) Ltd or Venus Remedies Ltd?

Market cap of Syncom Formulations (India) Ltd is 1,321 Cr while Market cap of Venus Remedies Ltd is 1,266 Cr

What are the key factors driving the stock performance of Syncom Formulations (India) Ltd and Venus Remedies Ltd?

The stock performance of Syncom Formulations (India) Ltd and Venus Remedies Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Syncom Formulations (India) Ltd and Venus Remedies Ltd?

As of May 5, 2026, the Syncom Formulations (India) Ltd stock price is INR ₹14.06. On the other hand, Venus Remedies Ltd stock price is INR ₹947.55.

How do dividend payouts of Syncom Formulations (India) Ltd and Venus Remedies Ltd compare?

To compare the dividend payouts of Syncom Formulations (India) Ltd and Venus Remedies Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.